Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Pipeline Review, H2 2017’, provides in depth analysis on Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Oncology, Cardiovascular, Gastrointestinal, Dermatology, Genetic Disorders, Immunology, Musculoskeletal Disorders, Respiratory, Infectious Disease, Male Health, Ophthalmology and Undisclosed under development targeting Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)

The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects

The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

EA Pharma Co Ltd

Gilead Sciences Inc

Iproteos SL

Shulov Innovative Science Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC

3.4.24.35) - Overview 7

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC

3.4.24.35) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 12

Products under Development by Universities/Institutes 16

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC

3.4.24.35) - Therapeutics Assessment 18

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC

3.4.24.35) - Companies Involved in Therapeutics Development 23

EA Pharma Co Ltd 23

Gilead Sciences Inc 23

Iproteos SL 24

Shulov Innovative Science Ltd 24

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC

3.4.24.35) - Drug Profiles 26

andecaliximab - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

AQU-005 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

AQU-010 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

AQU-118 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CALY-001 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

IPRO-003 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Monoclonal Antibodies to Inhibit MMP-2 and MMP-9 for Crohn's Disease - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

ND-336 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ND-478 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Protearin - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SI-1004 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

SI-1005 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ZEP-3 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC

3.4.24.35) - Dormant Products 46

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC

3.4.24.35) - Discontinued Products 49

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC

3.4.24.35) - Product Development Milestones 50

Featured News & Press Releases 50

Nov 02, 2016: Abzena Provides Update on GS-5745 50

Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis 50

Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain 50

May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology 51

Dec 26, 2011: New Antibodies Treat Autoimmune Disease in Mice 51

Oct 08, 2011: Researchers from Notre Dame university create breakthrough in neurological diseases 52

Oct 06, 2011: Notre Dame researchers make neurological disease breakthrough 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15

Number of Products under Investigation by Universities/Institutes, H2 2017 16

Products under Investigation by Universities/Institutes, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Stage and Route of Administration, H2 2017 20

Number of Products by Stage and Molecule Type, H2 2017 22

Pipeline by EA Pharma Co Ltd, H2 2017 23

Pipeline by Gilead Sciences Inc, H2 2017 24

Pipeline by Iproteos SL, H2 2017 24

Pipeline by Shulov Innovative Science Ltd, H2 2017 25

Dormant Products, H2 2017 46

Dormant Products, H2 2017 (Contd..1), H2 2017 47

Dormant Products, H2 2017 (Contd..2), H2 2017 48

Discontinued Products, H2 2017 49

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 19

Number of Products by Stage and Routes of Administration, H2 2017 19

Number of Products by Molecule Types, H2 2017 21

Number of Products by Stage and Molecule Types, H2 2017 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports